Carfilzomib
Also known as: Carfilzomib, CFZ, Kyprolis, NPI‑0052, PR-171, PR‑171
Source Carfilzomib at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Carfilzomib is an intravenously administered, epoxyketone‑based proteasome inhibitor approved for use in multiple myeloma. It is combined with dexamethasone, and often with other agents such as isatuximab or lenalidomide, to treat relapsed or refractory disease. Pre‑clinical work also suggests it can enhance novel KRAS‑G12D inhibitors, and it shows activity in Waldenström macroglobulinemia in later‑line settings.
Mechanism of Action
Carfilzomib irreversibly binds the chymotrypsin‑like β5 subunit of the 20S proteasome via its epoxyketone warhead, blocking protein degradation and causing accumulation of misfolded proteins. This triggers endoplasmic reticulum stress and apoptosis in malignant plasma cells. The proteasome blockade also sensitises tumours to other agents, as shown in KRAS‑G12D inhibitor studies where proteasome inhibition enhanced anti‑tumour activity.
What the Research Shows
Randomised phase 3 ENDEAVOR compared carfilzomib‑dex with bortezomib‑dex in relapsed/refractory myeloma, reporting a median progression‑free survival of 18.7 months versus 9.4 months (HR 0.53). The phase 3 IKEMA trial added isatuximab to carfilzomib‑dex, demonstrating further efficacy in relapsed disease. In the MIDAS phase 3 MRD‑guided trial, an induction regimen containing carfilzomib (Isa‑KRd) achieved high MRD‑negative rates (≈86 % at 10⁻⁶ sensitivity) without new safety signals. A 2024 Cancer Cell report showed that carfilzomib potentiated a KRAS‑G12D inhibitor (HRS‑4642) in pre‑clinical models. A 2025 Waldenström macroglobulinemia review listed carfilzomib among agents active in relapsed cases.
Reported Benefits
Clinical trials demonstrate that carfilzomib improves progression‑free survival compared with bortezomib in relapsed/refractory myeloma and can deepen MRD negativity when used in combination regimens. It retains activity in patients previously exposed to proteasome inhibitors and shows activity in Waldenström macroglobulinemia and pre‑clinical KRAS‑mutant tumours, suggesting a broad anti‑cancer potential.
Limitations of the Evidence
Evidence is strongest for multiple myeloma; data in other malignancies are limited to pre‑clinical or retrospective observations. ENDEAVOR and IKEMA were open‑label, and long‑term overall survival data remain immature. Safety concerns such as hypertension and cardiac events are noted but not fully quantified in the abstracts. The Waldenström activity is based on a review rather than prospective trials, and the KRAS‑G12D synergy is pre‑clinical only.
Safety Considerations
In ENDEAVOR, grade 3 or higher adverse events occurred in 48 % of carfilzomib patients, most commonly anemia (14 %), hypertension (9 %), thrombocytopenia (8 %) and pneumonia (7 %). On‑study deaths due to adverse events were 4 % in the carfilzomib arm. No new safety signals emerged in the MIDAS MRD‑guided study, but clinicians should monitor cardiovascular parameters and infection risk during therapy.
How It Is Administered
Carfilzomib is given by intravenous infusion, typically 20 mg/m² on days 1–2 of cycle 1 followed by 56 mg/m² thereafter, administered over 30 minutes. It is used in combination with dexamethasone and other agents such as isatuximab or lenalidomide, according to trial‑specific schedules.
Routes of Administration
Goals & Uses
- Proteasome pathway suppressionMechanistic/ResearchHigh
- Reduction of tumor burden in multiple myelomaOncologyHigh
- Multiple MyelomaOncologyHigh
- Treatment of newly diagnosed multiple myeloma (off-label/investigational)OncologyModerate
- Treatment of relapsed/refractory multiple myelomaOncologyHigh
Contraindications
- Severe cardiac dysfunction (ejection fraction < 40%)CardiovascularHigh
- Hypersensitivity to carfilzomibAllergyHigh
- Uncontrolled cardiac diseaseCardiovascularHigh
- Severe hepatic impairmentOrganModerateLiver function concerns
- Hypersensitivity to carfilzomib or any excipientsAllergyHigh
Adverse Effects
- Peripheral neuropathyNeurologicalUncommon
- HypertensionCardiovascularCommonHigh blood pressure
- ThrombocytopeniaHematologicCommonLow platelet count
- AnemiaHematologicCommonLow red blood cell count or hemoglobin
- FatigueGeneralCommonLow energy or tiredness
- Cardiac failureCardiovascularUncommon
- Infusion-related reactionsHypersensitivityUncommon
- Cardiac failure / cardiomyopathyCardiovascularUncommon
Drug Interactions
- Anticoagulants (e.g., warfarin)Moderate
- Antihypertensive agentsModerate
- Strong CYP3A4 inducers (e.g., rifampin)Moderate
- Strong CYP3A4 inhibitors (e.g., ketoconazole)Moderate
Population Constraints
- PregnancyReproductive SafetyAbsolute
- Renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- LactationReproductiveAbsolute
- Elderly patients (≥75 years)AgeRelative
- Severe renal impairment (CrCl < 30 mL/min)RenalRelative
Regulatory Status
- European UnionApprovedApproved: relapsed/refractory multiple myelomaEMA approval 2013
- United StatesApprovedApproved: relapsed/refractory multiple myelomaFDA approval 2012
- United KingdomApprovedApproved: relapsed/refractory multiple myelomaMHRA approval
FDA‑approved (2012) for multiple myeloma; also approved in EU and UK.
Evidence & Sources
- Journal ArticleModerateZhou C, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleModeratePerrot A, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleModerateGertz MA2025-01-01T00:00:00.000000Z
- Journal ArticleModerateDimopoulos MA, et al.2016-01-01T00:00:00.000000Z
- Journal ArticleModerateMoreau P, et al.2021-01-01T00:00:00.000000Z
- Journal ArticleModerateFricker LD2020-01-01T00:00:00.000000Z
Frequently Asked Questions
What type of cancer is carfilzomib primarily approved to treat?
Carfilzomib is approved for use in multiple myeloma, particularly in patients with relapsed or refractory disease after prior therapies.
How does carfilzomib differ from bortezomib?
Both inhibit the proteasome, but carfilzomib is an irreversible epoxyketone inhibitor given intravenously, whereas bortezomib is a reversible boronic‑acid agent that can be given intravenously or subcutaneously.
What are the main side effects to watch for?
The most frequent serious toxicities reported include anemia, hypertension, thrombocytopenia, and infections such as pneumonia; cardiac and cardiovascular monitoring is recommended.
Can carfilzomib be used in cancers other than myeloma?
Evidence outside myeloma is limited to pre‑clinical studies (e.g., KRAS‑G12D models) and a review noting activity in relapsed Waldenström macroglobulinemia, but no regulatory approvals exist for other malignancies.
Is carfilzomib given alone or with other drugs?
In clinical practice and trials, carfilzomib is combined with dexamethasone and often with additional agents such as isatuximab, lenalidomide, or other targeted therapies to enhance efficacy.
What is Carfilzomib?
Carfilzomib is an intravenously administered, epoxyketone‑based proteasome inhibitor approved for use in multiple myeloma. It is combined with dexamethasone, and often with other agents such as isatuximab or lenalidomide, to treat relapsed or refractory disease. Pre‑clinical work also suggests it can enhance novel KRAS‑G12D inhibitors, and it shows activity in Waldenström macroglobulinemia in later‑line settings.
What is Carfilzomib used for?
Carfilzomib is educationally associated with: Proteasome pathway suppression, Reduction of tumor burden in multiple myeloma, Multiple Myeloma, Treatment of newly diagnosed multiple myeloma (off-label/investigational), Treatment of relapsed/refractory multiple myeloma. Educational only — not medical advice.
How is Carfilzomib administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Carfilzomib?
Reported adverse effects include: Peripheral neuropathy, Hypertension, Thrombocytopenia, Anemia, Fatigue, Cardiac failure, Infusion-related reactions, Cardiac failure / cardiomyopathy. This list is not exhaustive — consult a qualified clinician.
Who should avoid Carfilzomib?
Recorded contraindications: Severe cardiac dysfunction (ejection fraction < 40%), Hypersensitivity to carfilzomib, Uncontrolled cardiac disease, Severe hepatic impairment, Hypersensitivity to carfilzomib or any excipients. Consult a qualified clinician before use.